Publication: Analytical and clinical performance of two homogeneous assays for measuring of LDL-cholesterol
Issued Date
2000-11-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-0034330301
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.83, No.SUPPL. 2 (2000)
Suggested Citation
Wattana Leowattana, Somjai Narkrung, Sasikant Pokum, Sudcharee Kiartivich Analytical and clinical performance of two homogeneous assays for measuring of LDL-cholesterol. Journal of the Medical Association of Thailand. Vol.83, No.SUPPL. 2 (2000). Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/26126
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Analytical and clinical performance of two homogeneous assays for measuring of LDL-cholesterol
Other Contributor(s)
Abstract
A clinical laboratory currently estimates LDL-Cholesterol (LDL-C) concentration using the Friedewald calculation, which requires fasting specimens and is subject to error with increasing triglycerides levels. We evaluated the analytical and clinical performance of the direct LDL-C assay from two companies, Roche Diagnostics (LDL-CRoche) and Wako Pure Chemical (LDL-CWako). Both methods meet current guidelines for precision with within-run coefficients of variation less than 3 per cent. The LDL-CRoche assay correlated well with the LDL-C from the Friedewald equation (LDL-CFried' r = 0.958, y = 0.85x + 17.08 mg/dL, n = 422). The LDL-CWako assay also correlated with the LDL-CFried (r = 0.946, y = 0.86x + 7.81 mg/dL, n = 422). In addition, at the medical decision cutoff points, LDL-CRoche assay and LDL-CWako showed positive predictive values of 87.44 per cent and 69.67 per cent respectively. We conclude that the LDL-CRoche assay meets the currently established analytical and clinical performance, but LDL-CWako assay meets only analytical performance. Clinical performance needs further evaluation.